PRICENTRIC BRIEF:
- Chengdu Healthcare Security Administration (CHSA) announced it has defined the scope of the protection for rare diseases in Chengdu in accordance with a medical, health commission, and financing-released circular seeking the establishment of a special fund and finetuned procurement methods for drugs for rare diseases
- To be included in this program, relevant drugs must be breakthrough, innovative orphan drugs whose indications match those found in the national rare disease catalogue, and their medical insurance payment is to be capped at less than 400,000 yuan per year and “personal burden” (i.e. out-of-pocket costs) at less than 60,000 yuan per year
- The first list of drugs includes the following products: Baiao Wanli Biotechnical’s sapropterin hydrochloride for tetrahydrobiopterin deficiency; Biogen’s Spinraza (nusinersen) for spinal muscular atrophy (SMA); Baiao Wanli Biotechnical’s elsosulfase alfa for mucopolysaccharidosis; Sanofi’s Cerezyme (imiglucerase) for Gaucher disease; Pfizer’s Vyndaqel/Vyndamax (tafamidis) for idiopathic cardiomyopathy (and transthyretin amyloid cardiomyopathy (ATTR-CM); Zhaoke Pharmaceutical’s treprostinil for pulmonary hypertension; and Sanofi’s avalglucosidase alfa for Pompe disease
THE DETAILS
CHENGDU, China – Chengdu Healthcare Security Administration (CHSA) announced it has defined the scope of the protection for rare diseases in Chengdu in accordance with the “Chengdu Medical Security Bureau, Chengdu Municipal Finance Bureau, Chengdu Municipal Health Commission’s Circular on Issues Concerning Drug Protection for Rare Disease,” a circular seeking the establishment of a special fund and finetuned procurement methods for drugs for rare diseases.
To be included in this program, relevant drugs must be breakthrough, innovative orphan drugs whose indications match those found in the national rare disease catalogue, and their medical insurance payment is to be capped at less than 400,000 yuan per year and “personal burden” (i.e. out-of-pocket costs) at less than 60,000 yuan per year.
Notably, drugs included in the National Reimbursed Drugs List (NRDL) will be excluded from this program, but newly-marketed orphan drugs approved in China that meet the aforementioned conditions and are not higher in cost than the annual drug costs of drugs with the same indication that have been included in the coverage can seek inclusion.
Drugs can be added or withdrawn, given the dynamics of the market, and a team of Chengdu experts (clinical, pharmacy, and policy experts) will review applications one-by-one and make recommendations.
The first list of drugs includes the following products:
- Baiao Wanli Biotechnical’s sapropterin hydrochloride for tetrahydrobiopterin deficiency
- Biogen’s Spinraza (nusinersen) for spinal muscular atrophy (SMA)
- Baiao Wanli Biotechnical’s elsosulfase alfa for mucopolysaccharidosis
- Sanofi’s Cerezyme (imiglucerase) for Gaucher disease
- Pfizer’s Vyndaqel/Vyndamax (tafamidis) for idiopathic cardiomyopathy (and transthyretin amyloid cardiomyopathy (ATTR-CM)
- Zhaoke Pharmaceutical’s treprostinil (branded as “Remodulin” by United Therapeutics) for pulmonary hypertension
- Sanofi’s avalglucosidase alfa for Pompe disease
Learn more about Pricentric ONE and our Global Pricing Solutions!
Contact us with your questions and global pricing needs, and an expert will follow up shortly.